Abbvie said on Friday it would record a charge of about $3.5 billion related to its experimental schizophrenia drug, ...
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback